AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer

Inclusion Criteria: * Pathologically confirmed adenocarcinoma of the prostate * Radiographic evidence of metastatic disease * Progressive disease meeting at least one of the following criteria: 1. a sequence of at least 2 rising PSA values measured at a minimum of 1 week apart with a 2 ng/mL minimum starting value, or 2. progression according to RECIST criteria for measurable lesions, or 3. appearance of 2 or more new lesions on bone scan. * History of prior taxane-based chemotherapy for metastatic prostate cancer * For patients without a history of surgical castration, continued GnRH analog administration is required * ECOG Performance status of 0 or 1 * Life expectancy ≥ 3 months Exclusion Criteria: * Treatment with external beam radiotherapy ≤ 14 days before enrollment or radiopharmaceutical ≤8 weeks * ≤ 4 weeks since receipt of most recent prior chemotherapy, non-GnRH analog hormonal therapy (except for continuing corticosteroids) or other systemic therapy to treat prostate cancer and \<6 weeks since receipt of prior bevacizumab. * Known CNS metastases (epidural disease is allowed if it has been treated and there is no progression in the treated area). * Significant cardiovascular disease * LVEF \< 50% by MUGA or ECHO * Treatment of infection with systemic anti-infectives within 7 days before enrollment (with the exception of uncomplicated urinary tract infection) * Concurrent or prior (within 7 days of enrollment) anticoagulation therapy, except that use of low dose coumarin-type anticoagulants or heparins for prophylaxis against central venous catheter thrombosis is allowed * Major surgical procedure ≤30 days before enrollment or not yet recovered from prior major surgery * Presence of peripheral edema \> Grade 2 * Known positive test for HIV, hepatitis C, chronic or active hepatitis B * Serious or non-healing wound * Unable to begin protocol specified treatment within 7 days after enrollment * Other investigational procedures are excluded.